



MISSION

Provide biological defense vaccines for protection of U.S. forces against the use of biological warfare (BW) agents (bacteria, toxins, and viruses) that will meet regulatory requirements for Food and Drug Administration (FDA) licensure.

DESCRIPTION AND SPECIFICATIONS

Biological Defense vaccines will provide protection against aerosol-delivered biological warfare agents. Immunization provides U.S. forces with additional protection, allowing commanders to continue operations in areas with known biological threats. The Biological Vaccine Program/Joint Vaccine Acquisition Program (JVAP) is responsible for transferring biological defense vaccines from research laboratories to the prime systems contractor for development, testing, FDA licensure and production of vaccines.

FOREIGN COUNTERPART

No known foreign counterpart

FOREIGN MILITARY SALES

None

PROGRAM STATUS

1QFY98 Awarded cost-plus-award-fee prime system contract to DynPort LLC as the prime system contractor.

2QFY99 MS0, Venezuelan Equine Encephalitis (VEE) vaccine.

1-2QFY00 Conducted manufacturing risk reduction studies, vaccine Phase 2a clinical trial, Vaccinia Immune Globulin (VIG) Intravenous (IV) consistency lot manufacture and Phase 2b clinical trial, vaccine and VIG assay validation for Vaccinia (Smallpox) Vaccine.

PROJECTED ACTIVITIES

FY00 Current good manufacturing practice (CGMP) pilot lot production and testing of VEE IA vaccine.


FY00-01 Continue developmental work for consistency model and surrogate model of Tularemia vaccine.

FY03 Continue advanced development of Q-Fever vaccine with FDA licensure, Milestone III and full-scale production of Q-Fever Vaccine.

Ongoing Complete pivotal clinical study and begin follow-on booster study for Pentavalent Toxoid (PBT), identify potential manufacturer of Botulinum Vaccines.

PRIME CONTRACTORS

DynPort, LLC (Reston, VA)



* See appendix for list of subcontractors

